# Efficacy and Safety of the N0750 Compared to Monotherapies in the Treatment of Painful Diabetic Peripheral Neuropathy

> **NCT06715462** · PHASE3 · WITHDRAWN · sponsor: **Eurofarma Laboratorios S.A.**

## Conditions studied

- Painful Diabetic Peripheral Neuropathy (PDPN)

## Interventions

- **DRUG:** N0750
- **DRUG:** Cymbalta®
- **DRUG:** Lyrica®

## Key facts

- **NCT ID:** NCT06715462
- **Lead sponsor:** Eurofarma Laboratorios S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2026-04
- **Primary completion:** 2028-03
- **Final completion:** 2028-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Strategic change in development priorities
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06715462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06715462, "Efficacy and Safety of the N0750 Compared to Monotherapies in the Treatment of Painful Diabetic Peripheral Neuropathy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06715462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*